Growth Metrics

Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Net Cash Flow readings, the most recent being $46.7 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 26.01% to $46.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $175.2 million, a 35.17% decrease, with the full-year FY2025 number at $191.6 million, down 49.56% from a year prior.
  • Net Cash Flow hit $46.7 million in Q1 2026 for Catalyst Pharmaceuticals, up from $19.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $172.8 million in Q1 2024 to a low of -$150.1 million in Q1 2023.
  • Median Net Cash Flow over the past 5 years was $42.3 million (2022), compared with a mean of $33.8 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 2267.58% in 2023 and later skyrocketed 351.38% in 2024.
  • Catalyst Pharmaceuticals' Net Cash Flow stood at $42.3 million in 2022, then tumbled by 60.63% to $16.7 million in 2023, then skyrocketed by 351.38% to $75.2 million in 2024, then tumbled by 74.37% to $19.3 million in 2025, then skyrocketed by 142.17% to $46.7 million in 2026.
  • The last three reported values for Net Cash Flow were $46.7 million (Q1 2026), $19.3 million (Q4 2025), and $37.1 million (Q3 2025) per Business Quant data.